Call for expression of interest for the selection of members of the Scientific Committee of the global health EDCTP3 joint undertaking
The Global Health EDCTP3 Joint Undertaking has now opened a call for expression of interest for the selection of the members of its Scientific Committee.
The Global Health EDCTP3 (GH EDCTP3) is a partnership between the European Union and the European and Developing Countries Clinical Trials Partnership (EDCTP) Association, whose members are several EU Member States and Associated countries and several African countries, and which builds on the first and second European and Developing Countries Clinical Trials Partnership (EDCTP) programmes.
The GH EDCTP3 aims at supporting clinical research to deliver solutions to reduce the burden of infectious diseases in sub-Saharan Africa and strengthen research capacities to prepare and respond to emerging infectious diseases. To achieve its objectives, the GH EDCTP3 is to be advised by a Scientific Committee.
Responsibilities and tasks
Some of the tasks the Scientific Committee will perform include:
- assist in the design of the strategic and scientific planning of the activities of the Global Health EDCTP3 Joint Undertaking.
- identify strategic needs and priorities for accelerating the development of new or improved clinical interventions, including the required training, networking and capacity building to be undertaken to achieve those objectives.
- advise on strategies to foster synergies and partnerships with all stakeholders.
Composition of the group
The Scientific Committee will be composed of fifteen to eighteen Members, ensuring a balanced representation of experts within the scope of the activities of the Joint Undertaking, including with respect to gender and geographical balance. Collectively, the members of the Scientific Committee will have the necessary competences and expertise covering the technical domain in order to make science-based recommendations to the joint undertaking.
The deadline for submission of applications is February 15, 2022.
Further information on the call for expression of interest